STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] Esperion Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi report beneficial ownership of 9,954,975 shares of Esperion Therapeutics common stock, representing 5.0% of the class based on 198,199,462 shares outstanding. The shares are held by Two Seas Global (Master) Fund LP, for which Two Seas Capital acts as investment adviser and has sole voting and dispositive power; TSC GP and Mr. Toussi are identified through their general partner and managing member roles.

The filing states the position is held in the ordinary course of business and not to change or influence control of the issuer. The disclosure quantifies position size and control over voting and disposition rights without indicating an intent to seek corporate control.

Positive

  • Beneficial ownership of 9,954,975 shares (~5.0% of outstanding common stock)
  • Reporting Persons have sole voting and sole dispositive power over the shares
  • Filing states holdings are in the ordinary course of business and not to change or influence control
  • Ownership held through an investment vehicle (Two Seas Global (Master) Fund LP) with clear adviser structure

Negative

  • None.

Insights

TL;DR: A 5.0% stake (9.95M shares) is disclosed with sole voting and dispositive power; this is a notable but non-controlling institutional position.

The filing shows Two Seas-affiliated entities and Sina Toussi collectively beneficially own 9,954,975 shares, calculated against 198,199,462 shares outstanding. The disclosure clarifies sole voting and dispositive authority over the position and includes a certification that the holdings are in the ordinary course of business, not intended to effect control. For investors, this documents a sizeable passive stake by an investment adviser rather than an overt control attempt.

TL;DR: Reporting persons hold sole voting/dispositive power over a 5% block but certify no intent to change issuer control.

The schedule identifies ownership through Two Seas Global (Master) Fund LP with Two Seas Capital as investment adviser, TSC GP as general partner, and Sina Toussi in managerial roles, each shown with sole voting and dispositive power for 9,954,975 shares. The certification in Item 10 explicitly states the shares were not acquired to influence control, which limits immediate governance implications, though any future change in intent would require updated disclosures.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Two Seas Capital LP
Signature:/s/ Sina Toussi
Name/Title:Sina Toussi / Managing Member of Two Seas Capital GP LLC, its General Partner
Date:08/13/2025
Two Seas Capital GP LLC
Signature:/s/ Sina Toussi
Name/Title:Sina Toussi / Managing Member
Date:08/13/2025
Sina Toussi
Signature:/s/ Sina Toussi
Name/Title:Sina Toussi / Self
Date:08/13/2025

FAQ

How many ESPR shares do Two Seas report owning?

9,954,975 shares of Esperion Therapeutics common stock are reported as beneficially owned.

What percentage of Esperion (ESPR) does the position represent?

5.0% of the class, calculated using 198,199,462 shares outstanding as disclosed by the issuer.

Who are the reporting persons on the Schedule 13G for ESPR?

Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi; the shares are held by Two Seas Global (Master) Fund LP.

Does Two Seas have voting or dispositive power over the ESPR shares?

Yes—the filing reports sole voting power and sole dispositive power over the 9,954,975 shares.

Is the stake reported as intended to influence control of Esperion?

No—the filing certifies the securities are held in the ordinary course of business and were not acquired to change or influence control.
Esperion Therape

NASDAQ:ESPR

ESPR Rankings

ESPR Latest News

ESPR Latest SEC Filings

ESPR Stock Data

730.17M
235.80M
0.56%
50.62%
11.08%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ANN ARBOR